Enter inventor name

Francis Thomas Boyle

This inventor holds 33 USPTO granted patents and 2 published patent applications, primarily in Anticancer Agents. Top assignees: Imperial Chemical Industries Limited, Astrazeneca Ab, Zeneca Limited. Active years: 1980-2010.

USPTO Granted Patents = 33 (Patent Applications = 2)

% Patents Active = 72.7

Average Co-Inventor Count = 2.4

ph-index = 10

Forward Citations = 220(Granted Patents)

Location History:

Cangleton, GB (1998)
Ends Congleton, GB (2001)
Congleton, GB (1981 - 2004)
Macclesfield Cheshire, GB (2004 - 2006)
Cheshire, GB (1991 - 2009)
Macclesfield, GB (1980 - 2010)

Company Filing History:

12 out of 3,840

Imperial Chemical Industries Limited

British Technology Group Limited

patents

5. 2 out of 62

Cancer Research Campaign Technology Limited

patents

6. 1 out of 10

Angiogene Pharmaceuticals Limited

patents

7. 1 out of 1,200

National Research Development Corporation

patents

8. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1980-2010

Loading Chart...

Areas of Expertise:

Antitumor Agents

Quinolines

Farnesyl Transferase Inhibitors

Cyclin Dependent Kinase Inhibitors

Indole Derivatives

Vascular Damaging Agents

Chemical Compounds

Tricyclic Compounds

Heterocyclic Compounds

Antifungal Azole Compounds

GnRH Antagonists

Purine Derivatives

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7820679 - N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl-phenyl)pyridine-3 sulphonamide as an anticancer agent (2010-10-26),

2. 7504416 - 4-substituted quinolines as antitumor agents (2009-03-17),

3. 7449489 - Indolylalkylamino-methylidenecarbamate derivatives useful as GnRH antagonists (2008-11-11),

4. 7402583 - Substituted quinolines as antitumor agents (2008-07-22),

5. 7253184 - 4-Substituted quinolines as antitumor agents (2007-08-07),

6. 7135502 - Colchinol derivatives as vascular damaging agents (2006-11-14),

7. 7101897 - Farnesyl transferase inhibitors (2006-09-05),

8. 7067532 - Substituted quinolines as antitumor agents (2006-06-27),

9. 7030123 - Indole derivatives with vascular damaging activity (2006-04-18),

10. 6946468 - 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors (2005-09-20),

11. 6777438 - Inhibitors of farnesyl protein transferase (2004-08-17),

12. 6677345 - Cyclin dependent kinase inhibitors (2004-01-13),

13. 6541491 - 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors (2003-04-01),

14. 6472435 - Anti-tumor agents (2002-10-29),

15. 6414145 - Imidazolyl compounds as inhibitors of farnesyl-protein tranferase (2002-07-02),

Title: The Legacy of Innovator Francis Thomas Boyle

Introduction: Francis Thomas Boyle, a visionary inventor hailing from Macclesfield, GB, stands as a testament to the power of innovation and individual impact on shaping the future. With 33 patents to his name, Boyle's relentless pursuit of excellence continues to inspire generations of inventors worldwide.

Latest Patents: Among Boyle's latest patents is the groundbreaking invention of N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-1,3,4-oxadiazol-2-yl-phenyl)pyridine-3 sulphonamide as an anticancer agent. Additionally, his work on 4-substituted quinolines as antitumor agents showcases his dedication to advancing the field of medicine.

Career Highlights: Boyle has made significant contributions during his tenure at renowned companies such as Imperial Chemical Industries Limited and AstraZeneca AB. His innovative spirit and commitment to groundbreaking research have left an indelible mark on the industry.

Collaborations: Throughout his career, Boyle has collaborated with esteemed colleagues such as James Michael Wardleworth and Zbigniew S. Matusiak. These collaborations have led to innovative breakthroughs and advancements in the field of pharmacology.

Conclusion: Francis Thomas Boyle's remarkable journey as an inventor underscores the transformative power of innovation and the lasting impact of one individual's dedication to pushing the boundaries of what is possible. His legacy serves as a beacon of inspiration for aspiring inventors and innovators worldwide.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]